2023 has been a year of highs and lows, a calendar of peaks and troughs, an epoch of mountains and valleys (all right Michael, put the thesaurus away...). From standing ovations for enfortumab vedotin and vorasidenib, to the ongoing black hole that is effective treatments for pancreatic and hepatocellular carcinomas. However, through it all the brightest minds in the field have continued to stoke the fires of hope with the development of novel antibody-drug conjugates, immunotherapies and clever applications of established treatments.

How fitting, then, that Josh and MIchael - definitely NOT amongst the brightest minds in the field, but two of the most enthusiastic - end their coverage of 2023 with a final glance into the future of lung cancer treatment. Keeping themselves to a (not so) strict five minute limit, they will look at four studies that may offer a glimpse into how lung cancer of both the small- and non-small cell variety may be managed.

We wish you a very happy and safe New Year, and a happy beginning to 2024.

Links to studies discussed in this episode (subscription may be required):

DS-7300: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDQwMw==

ETER701: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDgwNQ==

INTELLECT: https://pubmed.ncbi.nlm.nih.gov/36829154/

HERTHENA-Lung01: https://ascopubs.org/doi/full/10.1200/JCO.23.01476

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Additional sound effects courtesy of Pixabay: https://pixabay.com/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.